Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

MiNK Therapeutics, Inc. INKT NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
45/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$35.00
+159.1%

MiNK Therapeutics, Inc. (INKT) is a Biotechnology company in the Healthcare sector, currently trading at $13.51. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is INKT = $35 (+159.1% upside).

Valuation: INKT trades at a trailing Price-to-Earnings (P/E) of -0 (S&P 500 average ~25).

Net income is $12.5B (loss), growing at -38563.1%/yr. Net profit margin is 0% (thin). Gross margin is -1044.3% (+0 pp trend).

Balance sheet: total debt is $0 against $0 equity. Current ratio is 1.06 (adequate). Debt-to-assets is 0%. Total assets: $14.2B.

Analyst outlook: 4 / 5 analysts rate INKT as buy (80%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 11/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).

$35.00
▲ 159.07% Upside
Average Price Target
The 12-month price target for MiNK Therapeutics, Inc. is $35.00.

INKT SharesGrow Score Overview

54/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 11/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — INKT

✓
VALUE Pass
100/100
INKT trades at a trailing Price-to-Earnings (P/E) of -0 (S&P 500 average ~25). Analyst consensus target is $35, implying +159.1% from the current price $14. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
INKT: -100%/yr revenue is, -38563.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet INKT: Debt-to-Equity (D/E) ratio N/A, Current ratio is 1.06 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
11/100
INKT: Gross margin is -1044.3% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 11/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 4 / 5 analysts rate INKT as buy (80%). Analyst consensus target is $35 (+159.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range6.34-76
Volume116.76K
Avg Volume (30D)302.03K
Market Cap$67.09M
Beta (1Y)0.35
Share Statistics
EPS (TTM)-2.93
Shares Outstanding$4.27M
IPO Date2021-10-15
Employees23
CEOJennifer S. Buell
Financial Highlights & Ratios
Net Income$-12.49B
Total Cash$13.36B
Net Debt$-13.36B
Total Assets$14.24B
Price / Earnings (P/E)-4.6
Analyst Forecast
1Y Price Target$35.00
Target High$35.00
Target Low$35.00
Upside+159.1%
Rating ConsensusBuy
Analysts Covering5
Buy 80% Hold 20% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS6036932019

Price Chart

Track all markets on TradingView
INKT
MiNK Therapeutics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
6.34 52WK RANGE 76.00

People Also View

IMGN
IMGN
ImmunoGen, Inc.
$31.24
+0.02%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 DSGN
DSGN
Design Therapeutics, Inc.
$12.64
+2.35%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message